Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Services
    Clinical Research ServicesCommercial PositioningConsultingEarly PhaseStrategic SolutionsLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read more
    Innovation
    FIRECRESTICON Digital PlatformSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGEMedical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMS
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Harmonising data and services for more integrated decentralised clinical trials.
    ICON Digital Platform

    Harmonising data and services for more integrated decentralised clinical trials.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    3 - 7 June 2022 - The most comprehensive span of Oncology clinical development services
    ASCO 2022

    3 - 7 June 2022 - The most comprehensive span of Oncology clinical development services

    19 - 23 June 2022 - ICON's Jacqui Whiteway and Jane Galinsky will be speaking at this conference.
    DIA Global 2022

    19 - 23 June 2022 - ICON's Jacqui Whiteway and Jane Galinsky will be speaking at this conference.

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON is committed to making a positive impact on our people, environment and our community.
    Environmental, Social & Governance

    ICON is committed to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • EN | 日本語
  1. Home
  2. Insights
  3. Blog

Blog

  • 25 May 2022

    Why ICON is celebrating its first Inclusion Day

    Inclusion Day is an opportunity for us to come together in ICON as an organisation to think about the choices we make to further inclusion and diversity.

  • 19 May 2022

    Irritable Bowel Disease (IBD): A patient’s perspective

    Finding appreciation in the experience and treatment of IBD as a life-changing condition.

  • 17 May 2022

    My Clinical Research story – Jeslyne Margrette Isaac

    ICON's Jeslyne Margrette Isaac shares their personal experience with clinical trials.

  • 14 May 2022

    My Clinical Research story – Lisa Linn

    ICON's Lisa Linn shares their personal experience with clinical trials.

  • 14 May 2022

    My Clinical Research story – Jill Doherty

    ICON's Jill Doherty shares their personal experience with clinical trials.

  • 13 May 2022

    My Clinical Research story – Ellen Dalbo

    ICON's Ellen Dalbo shares their personal experience with clinical trials.

  • 13 May 2022

    Clinical Trials Day – Employee Testimonials

    ICON's Ben Prabhu, Amber Hallenborg, Shannon Jonietz, Rebekah Nolan, Kim Pope, Agustina Mazza, Linsey Barone, Catherine Bliss, Robyn Vancil, and Louisa Roberts share their personal experience with clinical trials.

  • 11 May 2022

    How joint venture models can boost Japan’s pharmaceutical industry

    Japan is the third-largest consumer of ethical drugs and the world’s third-largest economy; therefore, it is an important development centre for new medicines. However, there are various cultural and economic challenges in Japan that make it difficult to manage a fixed workforce against a variable portfolio of clinical research.

  • 27 April 2022

    NICE guidance on real-world evidence to usher innovative treatments

    NICE published new guidance to give patients early access to innovative treatments by allowing greater flexibility considering a broader evidence base, making it easier for innovative and promising treatments to reach the patient incorporating the usage of real-world evidence.

  • 21 March 2022

    Sharing my Down syndrome story - Beverly Romero

    Beverly Romero tells the story of her son Oliver.

  • 25 January 2022

    Progressive IVDR rollout made official

    In the fall of 2020, the European Commission issued a proposal to modify the implementation timeline for the new In Vitro Diagnostic Medical Devices Regulation (IVDR). Now, as of 15 December 2021, the European Parliament and the European Council have adopted this proposal, making the suggested progressive IVDR rollout timeline official.

  • 07 January 2022

    Combatting AMR with new tools to diagnose and treat infectious disease

    The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia has been a transformative medical achievement.

  • 07 December 2021

    Camaraderie and collaboration – what sets ICON apart

    ICON was recently named one of the World’s Best Employers for 2021 by global media company Forbes. This recognition is solely the result of employees’ on-the-job experiences and firsthand feedback.

  • 10 November 2021

    EC proposes extended transition period for IVDR compliance

    The European Commission has issued a proposal for a modified rollout of the new In Vitro Diagnostic Regulation (IVDR).

  • 01 November 2021

    Diverse clinical research starts with the healthcare workforce

    Diversity initiatives are a hallmark of clinical research. From US Food and Drug Administration (FDA)-penned guidance and pharma initiatives.

  • 31 October 2021

    How we can continue building a diverse, equal, and inclusive industry

    Workplace diversity encourages collaboration and innovation – every team member brings their own unique backgrounds, experiences, and perspectives at ICON.

  • 26 October 2021

    Navigating cardiovascular clinical trial adjudication during a respiratory pandemic

    COVID-19 disrupted clinical trials across all indications. Patient enrolment, participation, data collection, and more was forced to adapt to the challenges of this virus.

  • 19 October 2021

    The impact of the COVID-19 pandemic on mental health

    Learn how the ongoing state of the COVID-19 pandemic has affected the global mental health crisis.

  • 01 October 2021

    ICON Joins UNICEF Corporate Vaccine Alliance

    ICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance.

  • 20 September 2021

    Rare disease patients and advocates drive change in public policy

    Learn how patient advocacy organisations and rare disease communities are driving change in US public policy to make safe and effective treatment options available to all patients.

In this section
In this section
  • Digital Disruption
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
    • Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
    • Digital disruption in biopharma
    • Disruptive Innovation
    • Remote Patient Monitoring
      • Bring Your Own Device
      • Cybersecurity
        • Addressing cybersecurity for your medical device
      • Digital Endpoints
      • Transforming Medical Device Development with mHealth
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
  • Patient Centricity
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Developing Nurse-Centric Medical Communications
    • Diversity and inclusion in clinical trials
      • Diversity and inclusion in clinical trials whitepaper
    • Exploring the patient perspective from different angles
    • Patient safety and pharmacovigilance
      • Outsourced Pharmacovigilance Affiliate Solution
      • The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
    • Patient voice survey
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
  • Regulatory Intelligence
    • EU Regulations
      • IVDR Technical File Remediation
      • MDR and IVDR are Coming - Are you Prepared?
      • MDR / IVDR Brings Higher Costs and Bottlenecks
      • Seeking parallel consultation from regulators and HTA bodies in Europe
      • The IVDR journey
    • RACE for Children Act
    • Early engagement and regulatory considerations for biotech
    • Regulatory Intelligence Newsletter
    • Spotlight on regulatory reforms in China
    • Understanding the Periodic Benefit-Risk Evaluation Report
  • Therapeutics insights
    • Cardiovascular
      • Mitigating the impact of COVID-19 on cardiovascular trials
    • Cell and Gene Therapies
      • Cell and Gene ebook
      • Long-term follow-up studies of cell and gene therapies
      • Mainstreaming Cell & Gene Therapies
    • Central Nervous System
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Key Considerations in Chronic Pain Clinical Trials
    • Glycomics
    • Infectious Diseases
      • Antimicrobial Resistance
      • COVID-19 vaccine trials
      • HIV
    • NASH
      • The voice of NASH investigators
    • Oncology
    • Rare and orphan diseases
      • Advanced therapies for rare diseases
      • Identify and mitigate risks to rare disease clinical programmes
      • Leveraging historical data for use in rare disease trials
      • Natural history studies to improve drug development in rare diseases
      • Patient Centricity in Orphan Drug Development
  • Transforming Trials
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • Best practices to increase engagement with medical and scientific poster content
    • Decentralised & hybrid clinical trials
      • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
      • Decentralised and Hybrid clinical trials
      • Practical considerations in transitioning to hybrid or decentralised clinical trials
    • Functional model insights
      • Clinical trials in Japan: An enterprise growth and management strategy
      • The evolution of FSP: not just for large pharma
    • Implications of COVID-19 on statistical design and analyses of clinical studies
    • Improving pharma R&D efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Innovation in Clinical Trial Methodologies
    • Risk Based Quality Management
    • Supporting a top 10 pharma to transition to Veeva Vault platform
    • Transforming the R&D Model to Sustain Growth
  • Value Based Healthcare
    • US payers and PROs
    • Cardiovascular Medical Devices
    • COVID-19 navigating global market access
    • Ensuring scientific rigor in external control arms
    • Global Outcomes Benchmarking
    • Health technology assessment
    • Perspectives from US payers
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Medical communications in early phase product development
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • The affordability hurdle for gene therapies
    • The Role of ICER as an HTA Organisation
  • Blog
  • Videos
  • Webinar Channel
  • Diversity and inclusion in clinical trials
    • Diversity and inclusion in clinical trials whitepaper
  • Decentralised & hybrid clinical trials
    • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
    • Decentralised and Hybrid clinical trials
    • Practical considerations in transitioning to hybrid or decentralised clinical trials

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What's happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2022 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media